Unlike common nutraceuticals stocked in every health store, CJC-1295 moves through a global research peptide market that Rush residents navigate through international suppliers. The practical takeaway for Rush researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the framework for evaluating that quality is identical for researchers everywhere. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. This guide walks Rush researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Rush researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
The most reliable path to quality CJC-1295 is community research first — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. The HPLC analytical chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be at or above 98%. Community reputation in research forums is a useful additional signal to COA verification — vendors with sustained positive community feedback have earned that standing through repeat quality delivery. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Rush
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that proper COA verification addresses. PubMed and bioRxiv provide the most complete literature coverage for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over conference abstracts or single case observations.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
